“valeant-pharmaceuticals” Archives

in
Entry Author Date Location
Salix Bidding War Erupts as Endo Tops Valeant’s Offer 03/11/15 Raleigh Durham
Focused on Glaucoma, Aerie Looks Toward Unblinding Critical Data 03/03/15 New York
Cancer Immunotherapy Companies: Looking Forward and Looking Back 03/02/15 Seattle
Valeant to Acquire Specialty Pharma Salix in $14.5B Deal 02/22/15 Raleigh Durham
West Coast Biotech Roundup: Dendreon, Invitae, Juno, Regulus & More 02/12/15 Seattle
End of Dendreon: Valeant’s $400M is Sole Offer, Purchase is Next 02/10/15 Seattle
West Coast Biotech Roundup: Tracon, Mirati, Third Rock, & Dendreon 02/06/15 San Diego
Report: Troubled Salix Emerges as Valeant’s Latest Takeover Target 02/03/15 Raleigh Durham
Dendreon Gets $296M Bid From Valeant as Bankruptcy Auction Looms 01/30/15 Seattle
East Coast Biotech Roundup: Sarepta, Alkermes, Boston Biotech, & More 04/25/14 Boston
Kala Pharma Grabs $22.5M More For Eye Drugs 04/23/14 Boston
Alkermes Nabs $250M It Doesn’t Need, But Could Fend Off Barbarians 01/13/14 Boston
East Coast Life Sciences Roundup: Epizyme, Alkermes, Ophthotech, & More 05/31/13 Boston
With Fluorine Tech, SciFluor Aims to Vindicate “Me-Too” Drugs 02/25/13 Boston
In Comeback Study, Acadia Says Drug Controls Parkinson’s Psychosis 11/27/12 San Diego
Page 2 of 2 « previous page